Abstract
Interleukin-12 (IL-12) plays a pivotal role in regulating cellular immune responses involving autoimmunity, infectious disease, and cancer. Human recombinant (hr) IL-12 is being evaluated for therapy of human cancer. We investigated the potential of hrIL-12 to activate canine peripheral blood mononuclear cells (PBMC) using proliferation and cytotoxicity as readouts. Human rIL-12 caused increased proliferation of PBMC, and enhanced lysis of allogeneic canine tumor targets mediated by PBMC from normal dogs in vitro. In addition, antibody-dependent cellular cytotoxicity (ADCC) mediated by canine PBMC was enhanced by hrIL-12. These results indicate that hrIL-12 is recognized by canine immune cells, triggering a number of immune responses in canine PBMC, that may be important for immunotherapy of canine cancer. Information from this investigation provides impetus for evaluation of the effects of hrIL-12 on PBMC from tumor-bearing dogs and should be helpful in the development of hrIL-12 as an immune cell activator in vivo in the dog.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 189-201 |
| Number of pages | 13 |
| Journal | Veterinary immunology and immunopathology |
| Volume | 70 |
| Issue number | 3-4 |
| DOIs | |
| State | Published - Sep 20 1999 |
Bibliographical note
Funding Information:This work was supported by NIH grant CA01696 (SCH), Morris Animal Foundation grant 98CA-04 (SCH) and a University of Wisconsin, School of Veterinary Medicine Companion Animal Grant (BP). The authors would like to thank Dr. Paul Sondel and his laboratory for helpful suggestions and technical assistance.
Keywords
- Antibody-dependent cellular cytotoxicity
- Cytotoxicity
- Dog
- Interleukin-12
- Peripheral blood mononuclear cells
- Proliferation
